iOnctura
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Park Ave Sécheron 15, Geneva, Geneva, 12...Website
www.ionctura.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About iOnctura
iOnctura SA, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck and seed funded by M Ventures. It is a biopharmaceutical company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer.Explore more
iOnctura Org Chart
ML
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iOnctura your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on iOnctura recently announced quarterly report
Click to see if iOnctura had a recent Job posting/layoffs
iOnctura, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at iOnctura
Check out if iOnctura is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when iOnctura launches new products
Funding: Get notified immidiatlly once iOnctura has new funding data
Check if iOnctura has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at iOnctura
Find more new buyers
Company Profile Activity
Activity Insights
iOnctura is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iOnctura is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iOnctura.
iOnctura financials insights
Gather financial insights about iOnctura, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$22.8M
2022
Grant
$18.5M
2024
Series B
$85.9M
iOnctura Tech Stack
A closer look at the technologies used by iOnctura
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Research & Development, Sales, Business Development, Medical Research, Sales Operations
New Hire
Executive Move
Executive Moves, New Hire
iOnctura News & Media
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of roginolisib (PI3Kδ inhibitor) plus ruxolitinib in myelofibrosis (MF) patients unresponsive to Janus kinase (JAK) inhibitors Dual-target approach: combining PI3Kδ and...iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with pancreatic cancer at ESMO
Cambritaxestat, the first autotaxin (ATX) inhibitor to be investigated in cancer patients, meets its primary endpoint in a study to assess safety and anti- tumour responses in patients with metastatic pancreatic cancer Combining cambritaxestat with gemcitabine/nab-paclitaxel (GnP) was...iOnctura Expands Roginolisib Trials to the US, Advancing Multi-Indication Strategy in Oncology
US cancer centers begin enrolling patients into the global, randomized Phase II study of roginolisib in metastatic uveal melanoma Dana-Farber Cancer Institute launches new trial of roginolisib for Chronic Lymphocytic Leukemia, backed by Department of Defense grant GENEVA, AMSTERDAM and...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding iOnctura
Sign Up For FreeTo access detailed company insights
iOnctura SA, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck and seed funded by M Ventures. It is a biopharmaceutical company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer.... Read More
